Recent Event

<>

November 14, 2017

New York, NY

HBS Healthcare Alumni Association

Panelist : Norman Shelby

Real Endpoints LLC

Immuno-oncology treatments have provided renewed hope to cancer patients. Combination treatments bring the promise of increased efficacy with manageable side effects. Come hear from experts about what the future may bring. 

Moderator Norman Selby, Board of Trustees at Memorial Sloan Kettering, Executive Chairman of RealEndpoints and PAIGE.AI, former Senior Partner at McKinsey.

Panelists: Sophie Opdyke, VP, Immuno-Oncology Lead, Global Commercial Development at Pfizer Umer Raffat, Managing Director at Evercore ISI Peter Bach, Director, Center for Health Policy and Outcomes at MSK.

view event >

Recent Events

June 8, 2020 - June 12, 2020

Moderator: Jeffrey Berkowitz, CEO and Director

Real Endpoints

Real Endpoints is excited to be moderating this important panel on reimbursement of chronic rare and orphan disease therapies at the upcoming BIO International Digital Convention

view event >

May 19, 2020 12:00pm ET

Panelist: Jeffrey Berkowitz, CEO and Director
Roger Longman, Founder and Chairman

Real Endpoints

CELLO Health BioConsulting Webinar with Real Endpoints: In this senior executive webinar, we’ll give a boardroom presentation, and take your questions, on cancer’s unique payer situation and its stability — or instability. Our focus: how the informed biotech executive team manages early (and late) clinical and commercial development to ensure success not just with the FDA but in what may be a very different and less favorable reimbursement environment

view event >

May 4, 2020 12:30pm ET

HBO show!

Chief Clinical Officer: Jane F. Barlow, MD, MPH, MBA

Real Endpoints

Watch the replay of Real Endpoint’s Jane Barlow – joined by Congressman Scott Peters – speaking to the challenges of seeking reimbursement for cell and gene therapy during a time of upheaval.

view event >

October 16, 2019 - October 18, 2019

New York, NY

Speaker: Jeff Berkowitz
Roger Longman

Real Endpoints

Value-based pharma contracts have been rare in oncology relative to other therapeutic categories — and for a variety of good and bad reasons. But in the hyper-competitive future, risk-sharing will become a necessary component in every oncology company’s strategic toolkit. In five separate sessions at the value-based cancer summit in NY Oct 16-18, Real Endpoints CEO Jeff Berkowitz and Chairman Roger Longman will help lay out the challenges and the unexploited opportunities in oncology VBAs

view event >

October 13, 2019 - October 15, 2019

Laguna Beach, CA

Panel: Drug Pricing and Value Based Reimbursement

Jeff Berkowitz

Real Endpoints

Biotech’s CEOs at the annual Laguna meeting next week will be talking — as are their investors — about how to pay for innovation, particularly as the industry runs from major chronic disease to narrow orphan indications where pricing has been relatively protected. Real Endpoints’ CEO Jeff Berkowitz will be on a panel defining the increasing challenges of this approach, particularly given how competitive even the narrowest orphan conditions have become, and how companies must adapt to meet them.

October 2, 2019 1:15pm

San Diego, CA

Roger Longman

Real Endpoints

Real Endpoints Founder, Roger Longman, is looking forward to leading a robust discussion focused on solutions to creating access to cell and gene therapies — solutions that work for both payers and biopharma.

view event >